Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-90
SponsorSamsung Medical Center
About this trial
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
20 years
Patients requiring systemic chemotherapy with curative intent
Written informed consent
Disqualifiers
Myeloid malignancy
Multiple myeloma
Patients do not require systemic chemotherapy with curative intent
Trial population
Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Chemotherapy
DrugSystemic chemotherapy with curative intent
Treatment groups
600 Participants
are divided into 1 treatment groupGroup A: Lymphoma1 intervention
Trial outcomes
Primary outcomes
1
Response rate
response to chemotherapy
Time frame
3 months after chemotherapySecondary outcomes
1
Progression-free survival
Time to relapse/progression or any kinds of death
Time frame
3 year2
Overall survival
Time to any kinds of death
Time frame
3 year3
Biomarker
Development of biomarker predicting response and survival outcome
Time frame
3 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Samsung Medical Center
Lead sponsor
Samsung Genomic Institute
Collaborator
Source ClinicalTrials.gov